Integrated Diagnostics Holdings PLC Final Dividend Resolution -- Date Amendments (2438C)
17 Junio 2021 - 4:02AM
UK Regulatory
TIDMIDHC
RNS Number : 2438C
Integrated Diagnostics Holdings PLC
17 June 2021
Final Dividend Resolution - Date Amendments
17 June 2021
(Cairo and London) - Integrated Diagnostics Holdings ("IDH,"
"the Company" or "the Group"), a leading consumer healthcare
company with operations in Egypt, Jordan, Sudan, and Nigeria,
announces the following amendments to the dates contained in
resolution ten of the 2021 Notice of Annual General Meeting:
Resolution 10: To declare a final dividend of US$ 0.049 per
Share in respect of the year ended 31 December 2020 to be paid on
23 July 2021 to the holders of Shares on the register of members as
at the close of business on 2 July 2021, with an ex-dividend date
of 1 July 2021.
Amended Resolution 10: To declare a final dividend of US$ 0.049
per Share in respect of the year ended 31 December 2020 to be paid
on 29 July 2021 to the holders of Shares on the register of members
as at the close of business on 9 July 2021, with an ex-dividend
date of 8 July 2021.
The dates have been amended to accommodate IDH's Egypt-based
shareholders following the successful completion of the Company's
dual listing process.
Shareholders who have already cast a vote (by Proxy Form) in
respect of Resolution 10 should contact the Registrar immediately
if they wish to amend or withdraw their vote.
-Ends-
About Integrated Diagnostics Holdings (IDH)
IDH is a leading consumer healthcare company in the Middle East
and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The
Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar
in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar
Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record
for quality and safety has earned the Company a trusted reputation,
as well as internationally recognised accreditations for its
portfolio of over 2,000 diagnostics tests. From its base of 483
branches as of 31 March 2021, IDH will continue to add laboratories
through a Hub, Spoke and Spike business model that provides a
scalable platform for efficient expansion. Beyond organic growth,
the Group's expansion plans include acquisitions in new Middle
Eastern, African, and Asian markets where its model is well-suited
to capitalise on similar healthcare and consumer trends and capture
a significant share of fragmented markets. IDH has been a
Jersey-registered entity with a Standard Listing on the Main Market
of the London Stock Exchange (ticker: IDHC) since May 2015 with a
secondary listing on the EGX since May 2021 (ticker: IDHC.CA).
Learn more at idhcorp.com .
The person responsible for arranging the release of this
announcement is Nancy Fahmy, Investor Relations Director at
IDH.
Contact
Nancy Fahmy
Investor Relations Director
T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 |
nancy.fahmy@idhcorp.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSFASAWEFSEIM
(END) Dow Jones Newswires
June 17, 2021 05:02 ET (09:02 GMT)
Integrated Diagnostics (LSE:IDHC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Integrated Diagnostics (LSE:IDHC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
